{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:50:22Z","timestamp":1787028622346,"version":"build-2736575974"},"reference-count":104,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Rituximab is a chimeric anti-CD20 monoclonal antibody. It acts mainly through complement-dependent cytotoxicity on B cells expressing the CD20 marker. In this review, we analyse the efficacy and possible pitfalls of rituximab to treat nephrotic syndromes by taking into account pharmacological considerations and CD19 marker testing utility. Despite the fact that the drug has been in use for years, efficacy and treatment schedules in adults with nephrotic syndrome are still a matter of debate. Clinical trials have proven the efficacy and safety of rituximab in idiopathic membranous nephropathy. Data from observational studies also showed the efficacy of rituximab in minimal change disease and focal segmental glomerulosclerosis. Rituximab use is now widely recommended by new Kidney Disease Improved Outcome (KDIGO) guidelines in membranous nephropathy and in frequent-relapsing, steroid-dependent minimal change disease or focal segmental glomerulosclerosis. However, rituximab response has a large interindividual variability. One reason could be that rituximab is lost in the urine at a higher extent in patients with nonselective nephrotic proteinuria, exposing patients to different rituximab plasma levels. Moreover, the association between CD19+ levels and clinical response or relapses is not always present, making the use of this marker in clinical practice complex. High resolution flow cytometry has increased the capability of detecting residual CD19+ B cells. Moreover, it can identify specific B-cell subsets (including IgG-switched memory B cells), which can repopulate at different rates. Its wider use could become a useful tool for better understanding reasons of rituximab failure or avoiding unnecessary retreatments.<\/jats:p>","DOI":"10.3390\/jcm10245847","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T01:20:41Z","timestamp":1639444841000},"page":"5847","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Rituximab Therapy for Adults with Nephrotic Syndromes: Standard Schedules or B Cell-Targeted Therapy?"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4261-2323","authenticated-orcid":false,"given":"Lucia","family":"Del Vecchio","sequence":"first","affiliation":[{"name":"Department of Nephrology and Dialysis, Sant\u2019Anna Hospital, ASST Lariana, 22042 Como, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9949-3543","authenticated-orcid":false,"given":"Marco","family":"Allinovi","sequence":"additional","affiliation":[{"name":"Nephrology, Dialysis and Transplantation Unit, Careggi University Hospital, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0753-5414","authenticated-orcid":false,"given":"Paolo","family":"Rocco","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Universit\u00e0 degli Studi di Milano, Via G. Colombo, 71-20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9163-1515","authenticated-orcid":false,"given":"Bruno","family":"Brando","sequence":"additional","affiliation":[{"name":"Haematology Laboratory and Transfusion Centre, Legnano General Hospital (Milan), 20025 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.immuni.2009.01.006","article-title":"Cytokine-producing effector B cells regulate type 2 immunity to H. polygyrus","volume":"30","author":"Wojciechowski","year":"2009","journal-title":"Immunity"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2215\/CJN.09430915","article-title":"B Cells, Antibodies, and More","volume":"11","author":"Hoffman","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in primary membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.2215\/CJN.07210810","article-title":"Anti-phospholipase A2receptor antibodies correlate with clinical status in primary membranous nephropathy","volume":"6","author":"Hofstra","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1681\/ASN.2013040430","article-title":"Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy","volume":"25","author":"Hoxha","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/MNH.0000000000000697","article-title":"Membranous nephropathy: Current understanding of various causes in light of new target antigens","volume":"30","author":"Ronco","year":"2021","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.2215\/CJN.02500220","article-title":"Multi-autoantibody signature and clinical outcome in membranous nephropathy","volume":"15","author":"Ghiggeri","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nrneph.2016.147","article-title":"Minimal change disease and idiopathic FSGS: Manifestations of the same disease","volume":"12","author":"Maas","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_10","first-page":"604","article-title":"Autoimmunity in focal segmental glomerulosclerosis: A long-standing yet elusive association","volume":"7","author":"Ponticelli","year":"2020","journal-title":"Front. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"102671","DOI":"10.1016\/j.autrev.2020.102671","article-title":"Rituximab in adult minimal change disease and focal segmental glomerulosclerosis\u2014What is known and what is still unknown?","volume":"19","author":"Gauckler","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4161\/mabs.4.2.19286","article-title":"Rituximab in immunologic glomerular diseases","volume":"4","author":"Ejaz","year":"2012","journal-title":"MAbs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1053\/j.seminhematol.2010.01.001","article-title":"CD20 as a target for therapeutic Type I and II monoclonal antibodies","volume":"47","author":"Beers","year":"2010","journal-title":"Semin. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4081\/br.2019.26","article-title":"Monitoring anti-B cell immunotherapies in autoimmune diseases: Go with the flow. A position paper of the Italian Society for Clinical Cell Analysis (ISCCA)","volume":"1","author":"Brando","year":"2019","journal-title":"Beyond Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2217\/imt-2017-0178","article-title":"Consequences of B-cell-depleting therapy: Hypogammaglobulinemia and impaired B-cell reconstitution","volume":"10","author":"Sacco","year":"2018","journal-title":"Immunotherapy"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: Mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1126\/science.aaz9356","article-title":"Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab","volume":"367","author":"Chiang","year":"2020","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1046\/j.1365-2141.2001.03166.x","article-title":"Complement activation plays a key role in the side-effects of rituximab treatment","volume":"115","author":"Baars","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13075-016-1101-3","article-title":"Rituximab induces phenotypical and functional changes of NK cells in a non-malignant experimental setting","volume":"18","author":"Merkt","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1681\/ASN.2013040363","article-title":"Rituximab treatment prevents the early development of proteinuria following pig-to-baboon xeno-kidney transplantation","volume":"25","author":"Tasaki","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","article-title":"Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis","volume":"3","author":"Fornoni","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.kint.2021.05.015","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: A 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"MENTOR Investigators. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/ndt\/gfaa014","article-title":"The evolution of the therapeutic approach to membranous nephropathy","volume":"36","author":"Ponticelli","year":"2021","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11255-020-02633-5","article-title":"Rituximab for the management of idiopathic membranous nephropathy: A meta-analysis","volume":"53","author":"Huang","year":"2021","journal-title":"Int. Urol. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","volume":"99","author":"Logt","year":"2021","journal-title":"Kidney Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: The RI-CYCLO Randomized Trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40620-020-00781-6","article-title":"Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli\u2019s regimen in membranous nephropathy","volume":"34","author":"Fenoglio","year":"2021","journal-title":"J. Nephrol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"93438","DOI":"10.18632\/oncotarget.21833","article-title":"Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis","volume":"8","author":"Ren","year":"2017","journal-title":"Oncotarget"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/ckj\/sfy067","article-title":"Continuous B-cell depletion in frequently relapsing, steroid-dependent and steroid-resistant nephrotic syndrome","volume":"12","author":"Cortazar","year":"2018","journal-title":"Clin. Kidney. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00467-018-4166-1","article-title":"Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children","volume":"35","author":"Kamei","year":"2020","journal-title":"Pediatric Nephrol."},{"key":"ref_33","first-page":"gfab323","article-title":"Proteinuria selectivity index predicts response to rituximab in adults with minimal change disease and focal segmental glomerulosclerosis","volume":"12","author":"Allinovi","year":"2021","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","article-title":"Rituximab in Nephrotic Syndrome of Steroid-Dependent or Frequently Relapsing Minimal Change Disease Or Focal Segmental Glomerulosclerosis (NEMO) Study Group. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome","volume":"25","author":"Ruggenenti","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000477944","article-title":"High-dose rituximab ineffective for focal segmental glomerulosclerosis: A long-term observation study","volume":"46","author":"Roccatello","year":"2017","journal-title":"Am. J. Nephrol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1681\/ASN.2017090958","article-title":"Differentiating primary, genetic, and secondary FSGS in adults: A clinicopathologic approach","volume":"29","author":"Sethi","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Hansrivijit, P., Cheungpasitporn, W., Thongprayoon, C., and Ghahramani, N. (2020). Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: A systematic review and meta-analysis. BMC Nephrol., 21.","DOI":"10.1186\/s12882-020-01797-7"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: A multicentre, double-blind, randomised, placebo-controlled trial","volume":"384","author":"Iijima","year":"2014","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1681\/ASN.2014080799","article-title":"Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial","volume":"26","author":"Ravani","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e13157","DOI":"10.1097\/MD.0000000000013157","article-title":"Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea","volume":"97","author":"Ahn","year":"2018","journal-title":"Medicine"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","article-title":"Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic Syndrome: A Randomized Clinical Trial","volume":"172","author":"Basu","year":"2018","journal-title":"JAMA Pediatric"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.kint.2017.12.019","article-title":"Immunological remission in PLA2R-antibody-associated membranous nephropathy: Cyclophosphamide versus rituximab","volume":"93","author":"Dahan","year":"2018","journal-title":"Kidney Int."},{"key":"ref_43","first-page":"1558","article-title":"Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort","volume":"33","author":"Wang","year":"2018","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Pourcine, F., Dahan, K., Mihout, F., Cachanado, M., Brocheriou, I., Debiec, A., and Ronco, P. (2017). Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0173201"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.kint.2018.08.045","article-title":"Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody","volume":"95","author":"Dahan","year":"2019","journal-title":"Kidney Int."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1681\/ASN.2017070734","article-title":"Phospholipase A2 receptor 1 epitope spreading at baseline predicts reduced likelihood of remission of membranous nephropathy","volume":"29","author":"Debiec","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3389\/fmed.2020.00412","article-title":"Personalized medicine for PLA2R1-related membranous nephropathy: A multicenter randomized control trial","volume":"7","author":"Brglez","year":"2020","journal-title":"Front. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/ndt\/gfz041","article-title":"Rituximab bioavailability in primary membranous nephropathy","volume":"34","author":"Andreani","year":"2019","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00467-006-0427-5","article-title":"Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome?","volume":"22","author":"Smith","year":"2007","journal-title":"Pediatric Nephrol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5414\/CN110245","article-title":"Retrospective single-arm cohort study of steroid-dependent minimal change nephrotic syndrome treated with very low-dose rituximab","volume":"95","author":"Fujimoto","year":"2021","journal-title":"Clin. Nephrol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00467-009-1376-6","article-title":"Rituximab in refractory nephrotic syndrome","volume":"25","author":"Iijima","year":"2010","journal-title":"Pediatric Nephrol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.kint.2019.09.033","article-title":"Both the rituximab dose and maintenance immunosuppression in steroid-dependent\/frequently-relapsing nephrotic syndrome have important effects on outcomes","volume":"97","author":"Chan","year":"2020","journal-title":"Kidney Int."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00467-018-4052-x","article-title":"Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome","volume":"34","author":"Hogan","year":"2019","journal-title":"Pediatric Nephrol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00467-018-4172-3","article-title":"Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome","volume":"34","author":"Maxted","year":"2019","journal-title":"Pediatric Nephrol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: A 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/1060028018803587","article-title":"Rituximab exhibits altered pharmacokinetics in patients with membranous nephropathy","volume":"53","author":"Fogueri","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"ref_57","first-page":"1372859","article-title":"Kinetics of rituximab excretion into urine and peritoneal fluid in two patients with nephrotic syndrome","volume":"2017","author":"Stahl","year":"2017","journal-title":"Case Rep. Nephrol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jim.2017.09.001","article-title":"Detection and quantification of rituximab in the human urine","volume":"451","author":"Jacobs","year":"2017","journal-title":"J. Immunol. Methods"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s00467-015-3120-8","article-title":"Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome","volume":"30","author":"Counsilman","year":"2015","journal-title":"Pediatric Nephrol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.11791018","article-title":"High-dose rituximab and early remission in PLA2R1-related membranous nephropathy","volume":"14","author":"Dahan","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00415-018-9092-4","article-title":"Peripheral CD19(+) B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica\/neuromyelitis optica spectrum disorders","volume":"266","author":"Ellrichmann","year":"2019","journal-title":"J. Neurol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/acr2.11074","article-title":"Patterns of B Cell Repletion Following Rituximab Therapy in a Pediatric Rheumatology Cohort","volume":"1","author":"Mitchell","year":"2019","journal-title":"ACR Open Rheumatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/08916934.2014.914174","article-title":"Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease","volume":"47","author":"Venhoff","year":"2014","journal-title":"Autoimmunity"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/cei.12481","article-title":"Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: A prospective observational study","volume":"180","author":"Trouvin","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Reddy, V.R., Pepper, R.J., Shah, K., Cambridge, G., Henderson, S.R., Klein, C., Kell, L., Taylor, S.J., Isenberg, D.A., and Cragg, M.S. (2021). Disparity in Peripheral and Renal B-cell Depletion with Rituximab in Systemic Lupus Erythematosus: An Opportunity for Obinutuzumab?. Rheumatology, ahead of print.","DOI":"10.1093\/rheumatology\/keab827"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1093\/ndt\/gfr548","article-title":"Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome","volume":"27","author":"Kemper","year":"2012","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.2215\/CJN.09421010","article-title":"Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: A randomized controlled trial","volume":"6","author":"Ravani","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2215\/CJN.01180307","article-title":"Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy","volume":"2","author":"Cravedi","year":"2007","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/nep.13554","article-title":"Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy","volume":"24","author":"Ramachandran","year":"2019","journal-title":"Nephrology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","article-title":"Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children","volume":"24","author":"Kamei","year":"2009","journal-title":"Pediatric Nephrol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00467-009-1377-5","article-title":"Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine","volume":"25","author":"Fujinaga","year":"2010","journal-title":"Pediatric Nephrol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/ndt\/gfr405","article-title":"Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery","volume":"27","author":"Baudouin","year":"2012","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Ramachandran, R., Nayak, S., Kumar, V., Sethi, J., Minz, R., Kumar, V., Rathi, M., and Kohli, H.S. (2021). Rituximab in primary membranous nephropathy: A comparative study of three dosing regimens. Nephrol. Dial. Transpl., ahead of print.","DOI":"10.1093\/ndt\/gfab037"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/nep.13717","article-title":"Rituximab in maintaining remission in adults with podocytopathy","volume":"25","author":"Ramachandran","year":"2020","journal-title":"Nephrology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2215\/CJN.00570109","article-title":"Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis","volume":"4","author":"Segarra","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2215\/CJN.01080905","article-title":"Rituximab for idiopathic membranous nephropathy: Who can benefit?","volume":"1","author":"Ruggenenti","year":"2006","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/ndt\/gfu267","article-title":"Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome","volume":"30","author":"Sinha","year":"2015","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1681\/ASN.2015050523","article-title":"B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome","volume":"27","author":"Colucci","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s10157-017-1415-8","article-title":"Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion","volume":"22","author":"Sato","year":"2018","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00467-018-4063-7","article-title":"Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study","volume":"34","author":"Takahashi","year":"2019","journal-title":"Pediatric Nephrol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"28799","DOI":"10.18632\/oncotarget.25612","article-title":"Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome","volume":"9","author":"Fenoglio","year":"2018","journal-title":"Oncotarget"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10157-018-1630-y","article-title":"Therapeutic efficacy of rituximab for the management of adult-onset steroid-dependent nephrotic syndrome: A retrospective study","volume":"23","author":"Katsuno","year":"2019","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1002\/art.23902","article-title":"Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis","volume":"58","author":"Dass","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/cyto.b.21930","article-title":"The ISCCA flow protocol for the monitoring of anti-CD20 therapies in autoimmune disorders","volume":"100","author":"Gatti","year":"2021","journal-title":"Cytom. B Clin. Cytom."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.imbio.2016.11.011","article-title":"Kinetic analysis of changes in T- and B-lymphocytes after anti-CD20treatment in renal pathology","volume":"222","author":"Diekmann","year":"2017","journal-title":"Immunobiology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.kint.2017.01.012","article-title":"B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab","volume":"92","author":"Rosenzwajg","year":"2017","journal-title":"Kidney Int."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10157-016-1313-5","article-title":"Rituximab for nephrotic syndrome in children","volume":"21","author":"Iijima","year":"2017","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Leibler, C., Moktefi, A., Matignon, M., Debiais-Delpech, C., Oniszczuk, J., Sahali, D., Cohen, J.L., Grimbert, P., and Audard, V. (2018). Rituximab and fibrillary glomerulonephritis: Interest of B cell reconstitution monitoring. J. Clin. Med., 7.","DOI":"10.3390\/jcm7110430"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"7651024","DOI":"10.1155\/2016\/7651024","article-title":"Circulating (CD3(-)CD19(+)CD20(-)IgD(-)CD27(high)CD38(high)) plasmablasts: Promising cellular biomarker for immune activity for anti-PLA2R1 related membranous nephropathy?","volume":"2016","author":"Pozdzik","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaut.2016.03.010","article-title":"B cell depletion with rituximab in patients with rheumatoid arthritis: Multiplex bead array reveals the kinetics of IgG and IgA antibodies to citrullinated antigens","volume":"70","author":"Cambridge","year":"2016","journal-title":"J. Autoimmun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/rheumatology\/kex067","article-title":"Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples","volume":"56","author":"Reddy","year":"2017","journal-title":"Rheumatology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1182\/blood-2017-03-771832","article-title":"Obinutuzumab: What is there to learn from clinical trials?","volume":"130","author":"Cartron","year":"2017","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMc1308488","article-title":"Ofatumumab for rituximab-resistant nephrotic syndrome","volume":"370","author":"Basu","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000501858","article-title":"Accelerating the depletion of circulating anti-phospholipase A2 receptor antibodies in patients with severe membranous nephropathy: Preliminary findings with double filtration plasmapheresis and ofatumumab","volume":"144","author":"Gennarini","year":"2020","journal-title":"Nephron"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1681\/ASN.2021040561","article-title":"Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial","volume":"32","author":"Ravani","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.hemonc.2016.05.001","article-title":"Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab","volume":"10","author":"Jain","year":"2017","journal-title":"Hematol. Oncol. Stem. Cell Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/j.ajkd.2020.02.444","article-title":"Successful treatment of patients with refractory PLA2R-associated membranous nephropathy with obinutuzumab: A report of 3 cases","volume":"76","author":"Klomjit","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1756286418773025","DOI":"10.1177\/1756286418773025","article-title":"Ocrelizumab: A new milestone in multiple sclerosis therapy","volume":"11","author":"Mulero","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40620-020-00874-2","article-title":"Successful treatment of PLA 2 R1-antibody positive membranous nephropathy with ocrelizumab","volume":"34","author":"Schmidt","year":"2021","journal-title":"J. Nephrol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"eabc3961","DOI":"10.1126\/scitranslmed.abc3961","article-title":"Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia","volume":"13","author":"Crickx","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"602539","DOI":"10.3389\/fimmu.2021.602539","article-title":"Single-cell transcriptomic analyses define distinct peripheral b cell subsets and discrete development pathways","volume":"12","author":"Stewart","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"25690","DOI":"10.1073\/pnas.2012249117","article-title":"B cells reappear less mature and more activated after their anti-CD20-mediated depletion in multiple sclerosis","volume":"117","author":"Nissimov","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/24\/5847\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:47:00Z","timestamp":1760168820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/24\/5847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,13]]},"references-count":104,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["jcm10245847"],"URL":"https:\/\/doi.org\/10.3390\/jcm10245847","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,13]]}}}